Answers are grounded in this paper and cite their sources.
Haloferax mediterranei is a promising archaeon for producing the high-value-added biopolymer poly(3-hydroxybutyrate- co -3-hydroxyvalerate) (PHBV). However, its metabolic engineering has been largely hampered by the scarcity of efficient genome-editing tools. Here, we developed a versatile genome-editing platform by harnessing the endogenous type I-B CRISPR-Cas system. This toolkit enables highly efficient and precise gene deletion (>90% efficiency), multiplex editing, gene insertion, and large-scale chromosomal deletions (up to 24.8 kb). Additionally, we implemented a Cas3-mediated bidirectional deletion strategy facilitated by recombination inhibition. Using these tools, we constructed genome-reduced chassis with deletions of up to 43.2 kb, which exhibited superior PHBV synthesis without compromising cell growth. One optimal strain, ES1Δ123Δ24.9, achieved a PHBV production of 27.44 g/L from glucose in a 7-L bioreactor, with a conversion rate of 0.38 g PHBV/g glucose—the highest reported carbon source conversion rate among archaeal PHBV producers to date. These genome-reduced H. mediterranei strains represent an advanced chassis for the production of PHBV and other valuable biochemicals.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: